

Summary of Agents for Plaque Psoriasis and Psoriatic Arthritis

Adapted from More Than Skin in the Game - The Pharmacists Role in Treating Psoriasis and Psoriatic Arthritis

By Geoffrey Wall, PharmD, FCCP, BCPS

| Biologic | MOA | Dosage | Safety | Notes |
|------------------------|--------------------------|--------------------|------------------------------|---|
| Ixekizumab (Taltz) | IL-17 Antagonist | SQ 160/80 mg | Yeast infections, IBD flares | TB screening, no live vaccines |
| Guselkumab (Tremfya) | IL-23 Antagonist | SQ 100 mg | General infections | TB screening, no live vaccines, good data on fingernail PsO |
| Tildrakizumab (Ilumya) | IL-23 Antagonist | SQ 100 mg | General infections | TB screening, no live vaccines |
| Risankizumab | IL-23 Antagonist | Not yet approved | General infections | TB screening, no live vaccines |
| Tofacitinib (Xeljanz) | JAK Inhibitor | Oral 5 mg or 11 mg | Herpes infections | TB screening, no live vaccines |
| Clazakizumab | IL-6 Antagonist | Not yet approved | General infections | TB screening, no live vaccines |
| Neihulizumab | Activated T-Cell Blocker | Not yet approved | Unknown | Unknown |